178 related articles for article (PubMed ID: 16816234)
1. Prevalence of the metabolic syndrome among patients receiving clozapine.
Lamberti JS; Olson D; Crilly JF; Olivares T; Williams GC; Tu X; Tang W; Wiener K; Dvorin S; Dietz MB
Am J Psychiatry; 2006 Jul; 163(7):1273-6. PubMed ID: 16816234
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and associations of the metabolic syndrome among patients prescribed clozapine.
Ahmed M; Hussain I; O'Brien SM; Dineen B; Griffin D; McDonald C
Ir J Med Sci; 2008 Sep; 177(3):205-10. PubMed ID: 18461270
[TBL] [Abstract][Full Text] [Related]
3. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates.
Lamberti JS; Costea GO; Olson D; Crilly JF; Maharaj K; Tu X; Groman A; Dietz MB; Bushey MP; Olivares T; Wiener K
J Clin Psychiatry; 2005 Jul; 66(7):900-6. PubMed ID: 16013906
[TBL] [Abstract][Full Text] [Related]
4. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
[TBL] [Abstract][Full Text] [Related]
5. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients.
Lappin JM; Wijaya M; Watkins A; Morell R; Teasdale S; Lederman O; Rosenbaum S; Dick S; Ward P; Curtis J
Schizophr Res; 2018 Sep; 199():367-373. PubMed ID: 29486959
[TBL] [Abstract][Full Text] [Related]
6. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia.
Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J
Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178
[TBL] [Abstract][Full Text] [Related]
7. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
Henderson DC; Nguyen DD; Copeland PM; Hayden DL; Borba CP; Louie PM; Freudenreich O; Evins AE; Cather C; Goff DC
J Clin Psychiatry; 2005 Sep; 66(9):1116-21. PubMed ID: 16187768
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia.
Bai YM; Chen JY; Yang WS; Chi YC; Liou YJ; Lin CC; Wang YC; Lin CY; Su TP; Chou P
J Clin Psychiatry; 2007 Dec; 68(12):1834-9. PubMed ID: 18162013
[TBL] [Abstract][Full Text] [Related]
9. Metabolic monitoring and management among clozapine users.
Tso G; Kumar P; Jayasooriya T; Kisely S; Siskind D
Australas Psychiatry; 2017 Feb; 25(1):48-52. PubMed ID: 27590080
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia.
Lee NY; Roh MS; Kim SH; Jung DC; Yu HY; Sung KH; Chung IW; Youn T; Kang UG; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2013 Mar; 28(2):71-9. PubMed ID: 23211493
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.
Brunero S; Lamont S; Fairbrother G
Arch Psychiatr Nurs; 2009 Jun; 23(3):261-8. PubMed ID: 19446781
[TBL] [Abstract][Full Text] [Related]
12. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine.
Zhang R; Hao W; Pan M; Wang C; Zhang X; Chen DC; Xiu MH; Yang FD; Kosten TR; Zhang XY
Hum Psychopharmacol; 2011 Aug; 26(6):392-6. PubMed ID: 21826737
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype.
Zhang Y; Chen M; Chen J; Wu Z; Yu S; Fang Y; Zhang C
Psychopharmacology (Berl); 2014 May; 231(10):2211-8. PubMed ID: 24448899
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database.
Sicras-Mainar A; Blanca-Tamayo M; Rejas-Gutiérrez J; Navarro-Artieda R
Eur Psychiatry; 2008 Mar; 23(2):100-8. PubMed ID: 17904825
[TBL] [Abstract][Full Text] [Related]
16. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF
J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389
[TBL] [Abstract][Full Text] [Related]
17. Clozapine and cardiometabolic health in chronic schizophrenia: correlations and consequences in a clinical context.
Malhi G; Adams D; Plain J; Coulston C; Herman M; Walter G
Australas Psychiatry; 2010 Feb; 18(1):32-41. PubMed ID: 20039791
[TBL] [Abstract][Full Text] [Related]
18. The medical care of people with psychosis.
Lambert TJ
Med J Aust; 2009 Feb; 190(4):171-2. PubMed ID: 19220177
[No Abstract] [Full Text] [Related]
19. A Retrospective Chart Review of Screening on the Prevalence of Metabolic Syndrome (MetS) in an Irish Community Mental Health Service.
Cocoman AM; Gallagher D
Issues Ment Health Nurs; 2019 Oct; 40(10):895-901. PubMed ID: 31295053
[TBL] [Abstract][Full Text] [Related]
20. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Henderson DC; Cagliero E; Gray C; Nasrallah RA; Hayden DL; Schoenfeld DA; Goff DC
Am J Psychiatry; 2000 Jun; 157(6):975-81. PubMed ID: 10831479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
